High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence

Ähnliche Einträge

• Comments on “High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence”
  von: Enagnon Kazali Alidjinou
  Veröffentlicht: (2024)
• Reply to the Commentary of Alidjinou EK
  von: Kristen Andreatta, et al.
  Veröffentlicht: (2024)
• Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis
  von: Joseph J. Eron, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
  von: C. Martorell, et al.
  Veröffentlicht: (2025)
• Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pregnant women with HIV
  Veröffentlicht: (2024)